The Latest
-
FDA Rejects Intercept’s Liver Disease Drug, But This Analyst Still Anticipates Approval
-
Swiss pharma Helsinn, MEI scrap blood cancer therapy trial
-
Judge Sides With Guaido in $1 Billion Venezuela Gold Fight
-
Industry Analysts Just Upgraded Their OncoCyte Corporation (NYSEMKT:OCX) Revenue Forecasts By 14%